SBC Medical Group Holdings Incorporated reported its financial results for the second quarter of 2026, revealing a total revenue of $49.2 million, a 13.4% increase from $43.4 million in the same period last year. The company attributed this growth to a significant rise in management services revenue, which surged by 150% to $12.8 million, while franchising revenue saw a slight decline of 4.9% to $9.5 million. The net income attributable to the company reached $10.7 million, a substantial increase from $2.5 million in the prior year, reflecting a 357.5% rise.
For the first half of 2026, SBC Medical Group reported total revenues of $92.2 million, a modest increase of 1.7% compared to $90.7 million in the same period of 2025. However, net income attributable to the company decreased by 8.2% to $22 million from $24 million in the previous year. The company’s cash and cash equivalents rose to $184.3 million as of June 30, 2026, up from $163.8 million at the end of 2025, indicating improved liquidity.
The company has undergone significant operational changes, including the consolidation of Waqoo, Inc. and its subsidiary, which contributed $4.5 million in revenue for the quarter. SBC Medical Group also revised its management service agreements with several medical corporations, which is expected to enhance revenue by approximately $15 million annually. The company continues to focus on expanding its market presence in Japan, Vietnam, and Singapore, while also exploring global opportunities in the medical aesthetics sector.
In terms of operational metrics, SBC Medical Group's accounts receivable increased to $43.2 million, reflecting ongoing business growth. The company reported a working capital balance of $180.9 million, indicating a strong financial position to support its operations and growth initiatives. The company’s employee headcount has also increased, contributing to higher salaries and welfare expenses, which rose by 15.2% to $7.8 million for the quarter.
Looking ahead, SBC Medical Group remains optimistic about its growth trajectory, driven by strategic initiatives and market expansion. The company is committed to enhancing its service offerings and maintaining its competitive edge in the medical management sector. However, it also cautioned that fluctuations in foreign exchange rates, particularly the depreciation of the Japanese yen against the U.S. dollar, could impact future financial results. The company plans to continue monitoring its financial performance and market conditions closely as it navigates these challenges.
About SBC Medical Group Holdings Inc
SBC Medical Group is a management company specializing in operating and supporting cosmetic treatment centers globally. It provides franchise management, marketing, staff recruitment, training, medical supplies, and licensing of proprietary technologies. Its core markets include Japan, Vietnam, Singapore, and the U.S., with a focus on high-quality aesthetic medical services. The company leverages advanced technology, brand licensing, and comprehensive operational support to differentiate in the cosmetic healthcare industry.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov